Key result
Rivaroxaban at a dose of twice daily administered within 1 year after acute coronary syndrome helps reduce cardiovascular and total mortality and the risk of stent thrombosis.
Why the study?
Does rivaroxaban reduce mortality and stent thrombosis in patients with acute coronary syndrome?
Does rivaroxaban reduce mortality and stent thrombosis in patients with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
A review of randomized clinical trials suggests that rivaroxaban 2.5 mg twice daily is an effective strategy to reduce mortality and stent thrombosis in patients following acute coronary syndrome.
The review discusses the results of using oral anticoagulants to improve the prognosis of patients after exacerbation of coronary artery disease. Based on a review of the available randomized clinical trials, the authors conclude that rivaroxaban at a dose of 2.5 mg twice daily has the best efficacy/safety ratio. Administration of rivaroxaban at the mentioned dose within 1 year after the development of acute coronary syndrome helps to reduce cardiovascular and total mortality and the risk of stent thrombosis.
No takes yet. Share an insight, caveat, or question.
N. B. Perepech (2017) conducted a review in Acute coronary syndrome. Rivaroxaban was evaluated on Cardiovascular and total mortality and the risk of stent thrombosis. Rivaroxaban at a dose of twice daily administered within 1 year after acute coronary syndrome helps reduce cardiovascular and total mortality and the risk of stent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: